Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on August 10, 2023. The filing reports financial results for the three and six months ended June 30, 2023, along with recent corporate updates. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol SLRX.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for specific financial figures.
Material Changes
The filing text does not contain specific quantitative comparisons to prior periods. It indicates that material updates regarding operations and financial condition were announced in the referenced press release.
Guidance, Outlook, and Risks
The filing includes "other recent corporate updates" but does not detail specific guidance, outlook, or risk factors within the text provided. The document explicitly states that the information furnished in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics Inc.
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures for the period ended June 30, 2023.
- Confirm the status of the company's clinical pipeline and corporate updates mentioned in the press release.
- Note that the financial data in this 8-K is furnished, not filed, and may not be incorporated by reference into future SEC filings.